Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
Open Access
- 24 July 1997
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (4) , 223-229
- https://doi.org/10.1056/nejm199707243370402
Abstract
Treatment with interferon prolongs survival in chronic myelogenous leukemia. We conducted a clinical trial to assess the efficacy of treatment with a combination of interferon and cytarabine.Keywords
This publication has 25 references indexed in Scilit:
- Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α TherapyAnnals of Internal Medicine, 1995
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994
- Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabineAmerican Journal of Hematology, 1993
- Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous LeukemiaAnnals of Internal Medicine, 1991
- Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine ArabinosideLeukemia & Lymphoma, 1991
- Characteristics of accelerated disease in chronic myelogenous leukemiaCancer, 1988
- Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemiaLeukemia Research, 1988
- Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemiaCancer, 1987
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958